The significance ofhig senum concentrations of low molecular weight Clq (LMW-Clq) in patients with systemic lupus erythematosus (SLE) 
major exacerbation requiring admission to hospital, showed that LMW-Clq increased in paralel with anti-dsDNA, reachingpeakvalues of more than 2000%/o of normal just before or at the time of clinical relapse and decreasing during convalescence. Most marked increases in LMW-Clq were noted in the three patients in whom Clq concentrations remained normal, whereas increases were less in the three patients who had strongly depressed concentrations of normal Clq. A study of Clq biosynthesis by macrophages cultured from patients with SLE and high serum concentrations of LMW-Clq did not show impaired secretion of normal Clq in favour of LMWClq, but indicated that serum concentrations of LMW-Clq may reflect the synthetic rate of Clq in vivo. The results show that increased serum concentrations of LMW-Clq may be helpful in diagnosing SLE and suggest that serial determination of LMW-Clq in serum may have predictive value in monitoring patients with SLE.
It is generally assumed that activation of the classical pathway of complement occurs in the pathogenesis of systemic lupus erythematosus (SLE) and that depressed concentrations of Clq, C4, and C3 in serum reflect this activation in vivo. Therefore, serial measurement of these components in serum has been widely used in the assessment of disease activity in SLE.'
Although several studies showed the predictive value of serial determination of complement profiles in combination with monitoring of serum titres ofanti-dsDNA,2' others questioned the reliability and usefulness of complement concentrations as serological markers of disease activity.5 6 This controversy is undoubtedly maintained by the fact that concentrations of complement components in serum reflect the net result of synthesis and catabolism and may not reflect the actual metabolism of these proteins in SLE.
In a previous study we reported increased concentrations of low molecular weight Clq (LMW-Clq) in serum samples from 54 patients with SLE who had not been selected for their disease The aim of the work described here was to answer these questions.
Patients and methods

PATIENTS AND SERUM SAMPLES
Eighty two patients with SLE fulfilling the revised American Rheumatism Association (ARA) criteria were entered into the study.'0 Blood samples from 71 of these patients were obtained within six weeks after the appearance of one or more of the following symptoms: skin lesions, including rashes, palpable purpura, and digital infarctions (present in 34 patients); arthralgia or arthritis (in 32 patients); haematological abnormalities-that is, haemolytic anaemia, thrombocytopenia or leucopenia (in 38 patients); pleuritis (in 22 3), but also by markedly depressed serum Clq, starting several months before clinical signs of nephritis were apparent. Concentrations of Clq returned to normal during convalescence except in patient S who died of sepsis as a complication of severe skin ulcera. Serum concentrations of LMW-Clq fluctuated in a manner opposite to those of normal Clq and more similar to titres of anti-dsDNA: they 'peaked' in the period of severe relapse and decreased during convalescence. When profiles of LMW-Clq were studied in three other patients who had normal serum concentrations of Clq in the period of rising anti-dsDNA that preceded major flares, unexpected results were obtained: the increase in LMW-Clq was much more pronounced in these patients, reaching values of more than 20 times the normal concentration (fig 4) . None of these patients had severe renal disease, though patients H and W had mild renal symptoms about two weeks after the anti-dsDNA peak. In 
